TY  - JOUR
AU  - Habl, Gregor
AU  - Hatiboglu, Gencay
AU  - Edler, Lutz
AU  - Uhl, Matthias
AU  - Krause, Sonja
AU  - Roethke, Matthias
AU  - Schlemmer, Heinz-Peter
AU  - Hadaschik, Boris
AU  - Debus, Jürgen
AU  - Herfarth, Klaus
TI  - Ion Prostate Irradiation (IPI) - a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique.
JO  - BMC cancer
VL  - 14
IS  - 1
SN  - 1471-2407
CY  - London
PB  - BioMed Central
M1  - DKFZ-2017-00755
SP  - 202
PY  - 2014
AB  - Due to physical characteristics, ions like protons or carbon ions can administer the dose to the target volume more efficiently than photons since the dose can be lowered at the surrounding normal tissue. Radiation biological considerations are based on the assumption that the α/β value for prostate cancer cells is 1.5 Gy, so that a biologically more effective dose could be administered due to hypofractionation without increasing risks of late effects of bladder (α/β = 4.0) and rectum (α/β = 3.9).The IPI study is a prospective randomized phase II study exploring the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique. The study is designed to enroll 92 patients with localized prostate cancer. Primary aim is the assessment of the safety and feasibility of the study treatment on the basis of incidence grade III and IV NCI-CTC-AE (v. 4.02) toxicity and/or the dropout of the patient from the planned therapy due to any reason. Secondary endpoints are PSA-progression free survival (PSA-PFS), overall survival (OS) and quality-of-life (QoL).This pilot study aims at the evaluation of the safety and feasibility of hypofractionated irradiation of the prostate with protons and carbon ions in prostate cancer patients in an active beam technique. Additionally, the safety results will be compared with Japanese results recently published for carbon ion irradiation. Due to the missing data of protons in this hypofractionated scheme, an in depth evaluation of the toxicity will be created to gain basic data for a following comparison study with carbon ion irradiation.Clinical Trial Identifier: NCT01641185 (clinicaltrials.gov).
KW  - Prostate-Specific Antigen (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:24641841
C2  - pmc:PMC3995364
DO  - DOI:10.1186/1471-2407-14-202
UR  - https://inrepo02.dkfz.de/record/120173
ER  -